Bellevue Group’s Oric Pharmaceuticals ORIC Stock Holding History

Bellevue Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,706	Closed	-$79.4K	–	183
2025 Q4	$79.4K	Buy	+9,706	New	+$112K	﹤0.01%	169

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bellevue Group's ORIC Position: Q1 2026 in Review

Bellevue Group sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 9,706 shares — an estimated $79.4K sold.

Bellevue Group first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $79.4K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Bellevue Group reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 9,706 Oric Pharmaceuticals shares in Q1 2026, an estimated $79.4K.
Bellevue Group first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bellevue Group's Oric Pharmaceuticals position peaked at $79.4K in Q4 2025.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.